Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $33.17 Average PT from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $33.1667.

A number of equities analysts have issued reports on the company. Wedbush increased their price target on Tyra Biosciences from $30.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Oppenheimer reaffirmed an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a research note on Wednesday, September 10th. Wall Street Zen lowered Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th. Finally, Raymond James Financial initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price objective for the company.

Insiders Place Their Bets

In related news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the director owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. This trade represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TYRA. Public Employees Retirement System of Ohio lifted its position in shares of Tyra Biosciences by 34.8% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 24,962 shares of the company’s stock valued at $349,000 after acquiring an additional 6,450 shares in the last quarter. HighVista Strategies LLC raised its stake in Tyra Biosciences by 163.6% during the 3rd quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock valued at $921,000 after purchasing an additional 40,850 shares during the period. Commodore Capital LP raised its stake in Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after purchasing an additional 275,000 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Tyra Biosciences in the third quarter valued at $2,612,000. Finally, Ameriprise Financial Inc. boosted its position in shares of Tyra Biosciences by 8.1% in the third quarter. Ameriprise Financial Inc. now owns 87,107 shares of the company’s stock worth $1,219,000 after buying an additional 6,505 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Trading Down 1.9%

Tyra Biosciences stock opened at $25.47 on Tuesday. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $26.34. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -13.62 and a beta of 1.08. The company’s 50-day moving average price is $19.51 and its two-hundred day moving average price is $14.37.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). Research analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.